So it seems that the current diagnostic modalities for establishing
diagnosis are not very good and are somewhat subjective and
expensive. Now if you are using these same modalities to decide which
patients to include in the arm of the study which represents Alzheimers
patients, there will be some inherent difficulties in the certainty with
which the Lympro results come back.